Although their binding energies are not as high as those of FDA-approved KRAS G12C inhibitors (sotorasib and adagrasib), combined therapies of apigenin and tested flavonoids with the aforementioned inhibitors may reduce side effects and resistance to treatment that have been recently reported in lung and colorectal cancer patients treated with sotorasib or adagrasib [67]. Here, KRAS is linked to colorectal cancer.